No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 3.9491
- -0.5509-12.24%
Trading Jul 22 15:21 ET
19.71MMarket Cap-1316P/E (TTM)
4.6884High3.8619Low294.31KVolume4.5700Open4.5000Pre Close1.27MTurnover6.39%Turnover RatioLossP/E (Static)4.99MShares4.688452wk High3.16P/B18.18MFloat Cap1.810052wk Low--Dividend TTM4.60MShs Float1419.0000Historical High--Div YieldTTM18.37%Amplitude1.5200Historical Low4.3160Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | EF Hutton Initiates Coverage On Can Fite Biofarma With Buy Rating, Announces Price Target of $10
Can Fite Biofarma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/17/2024 167.38% EF Hutton → $10 Initiates Coverage On → Buy 05/09/2024 381.28% HC Wainwright & Co. $18
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and
Can-Fite BioPharma Shareholders Approve Key Proposals
Improvement in Patient With Decompensated Liver Cirrhosis Upon Treatment With Namodenoson
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a
Comments
$Can-Fite BioPharma(CANF.US$ Can-fite Biopharma Says Its Veterinary Partner Vetbiolix Reported Positive Results In An Osteoarthritis Multicenter Clinical Study In Dogs Treated With Piclidenoson
Can-Fite BioPharma: New Findings Highlight Namodenoson's Mechanism in Liver Protection and Cancer Treatment.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology firm dedicated to developing innovative treatments for oncological and inflammatory diseases, has unveiled new findings concerning its small molecule drug, Namodenoson. These recent discoveries shed light on the mechanisms by which Namodeno...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology firm dedicated to developing innovative treatments for oncological and inflammatory diseases, has unveiled new findings concerning its small molecule drug, Namodenoson. These recent discoveries shed light on the mechanisms by which Namodeno...
$Can-Fite BioPharma(CANF.US$ Benzinga· 2 mins ago
Rhe FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
Rhe FDA Has Granted Investigational New Drug Clearance For Can-Fite Biopharma's Namodenoson, For Metabolic Dysfunction-Associated Steatohepatitis, Also Known As Non-alcoholic Steatohepatitis, For The Company's Ongoing Phase 2B Study
1
$Can-Fite BioPharma(CANF.US$
NEWS
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
NEWS
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
$Can-Fite BioPharma(CANF.US$ Can-Fite BioPharma Announced Notice Of Allowance In Canada For Its Patent Application Regarding Se Of Namodenoson For The Reduction Of Liver Fat In Patients With NASH
5
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
